Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: A meta-analysis

Adel Shahnam; Zainab Ridha; Michael D. Wiese; Ganessan Kichenadasse; Michael Joseph Sorich

doi:10.2217/pgs-2016-0102

Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: A meta-analysis

Adel Shahnam, Zainab Ridha, Michael D. Wiese, Ganessan Kichenadasse, Michael Joseph Sorich

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

Aims: Oxaliplatin-based chemotherapy for colorectal cancer demonstrates interindividual variability in response, and polymorphisms of ERCC1, ERCC2, XRCC1, GSTP1 and GSTM1 genes may be contributing factors. Additionally, the effect of these genotypes may differ between ethnic groups. Material & Methods: A meta-analysis of the association between these genotypes and response, progression-free survival and overall survival (OS) for patients with colorectal cancer treated with oxaliplatin-based therapy is reported. Results: ERCC1 C118T (TT vs CC OS [hazard ratio (HR): 2.59; p = 0.001]), ERCC2 A2251C (CC or AC vs AA OS [HR: 1.53; p = 0.04]) and GSTP1 A313G (GG vs AA OS, [HR: 0.47; p < 0.001]) polymorphisms were associated with survival. The effect size may be larger for ERCC1 C118T and XRCC1 G1196A in Asian compared with Caucasian populations. No association was apparent for the GSTM1 genotype. Conclusion: ERCC1 C118T, ERCC2 A2251C and GSTP1 A313G polymorphisms were associated with clinical outcome.

Original language	English
Pages (from-to)	1725-1732
Number of pages	8
Journal	Pharmacogenomics
Volume	17
Issue number	15
DOIs	https://doi.org/10.2217/pgs-2016-0102
Publication status	Published - Oct 2016

Keywords

colorectal neoplasm
ERCC1
ERCC2
GSTM1
GSTP1
meta-analysis
oxaliplatin
pharmacogenetic
XRCC1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/pgs-2016-0102Licence: In Copyright

Cite this

@article{4776b2c341dd44b58fae0618975c43a4,

title = "Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: A meta-analysis",

abstract = "Aims: Oxaliplatin-based chemotherapy for colorectal cancer demonstrates interindividual variability in response, and polymorphisms of ERCC1, ERCC2, XRCC1, GSTP1 and GSTM1 genes may be contributing factors. Additionally, the effect of these genotypes may differ between ethnic groups. Material & Methods: A meta-analysis of the association between these genotypes and response, progression-free survival and overall survival (OS) for patients with colorectal cancer treated with oxaliplatin-based therapy is reported. Results: ERCC1 C118T (TT vs CC OS [hazard ratio (HR): 2.59; p = 0.001]), ERCC2 A2251C (CC or AC vs AA OS [HR: 1.53; p = 0.04]) and GSTP1 A313G (GG vs AA OS, [HR: 0.47; p < 0.001]) polymorphisms were associated with survival. The effect size may be larger for ERCC1 C118T and XRCC1 G1196A in Asian compared with Caucasian populations. No association was apparent for the GSTM1 genotype. Conclusion: ERCC1 C118T, ERCC2 A2251C and GSTP1 A313G polymorphisms were associated with clinical outcome.",

keywords = "colorectal neoplasm, ERCC1, ERCC2, GSTM1, GSTP1, meta-analysis, oxaliplatin, pharmacogenetic, XRCC1",

author = "Adel Shahnam and Zainab Ridha and Wiese, {Michael D.} and Ganessan Kichenadasse and Sorich, {Michael Joseph}",

year = "2016",

month = oct,

doi = "10.2217/pgs-2016-0102",

language = "English",

volume = "17",

pages = "1725--1732",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "15",

}

TY - JOUR

T1 - Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer

T2 - A meta-analysis

AU - Shahnam, Adel

AU - Ridha, Zainab

AU - Wiese, Michael D.

AU - Kichenadasse, Ganessan

AU - Sorich, Michael Joseph

PY - 2016/10

Y1 - 2016/10

N2 - Aims: Oxaliplatin-based chemotherapy for colorectal cancer demonstrates interindividual variability in response, and polymorphisms of ERCC1, ERCC2, XRCC1, GSTP1 and GSTM1 genes may be contributing factors. Additionally, the effect of these genotypes may differ between ethnic groups. Material & Methods: A meta-analysis of the association between these genotypes and response, progression-free survival and overall survival (OS) for patients with colorectal cancer treated with oxaliplatin-based therapy is reported. Results: ERCC1 C118T (TT vs CC OS [hazard ratio (HR): 2.59; p = 0.001]), ERCC2 A2251C (CC or AC vs AA OS [HR: 1.53; p = 0.04]) and GSTP1 A313G (GG vs AA OS, [HR: 0.47; p < 0.001]) polymorphisms were associated with survival. The effect size may be larger for ERCC1 C118T and XRCC1 G1196A in Asian compared with Caucasian populations. No association was apparent for the GSTM1 genotype. Conclusion: ERCC1 C118T, ERCC2 A2251C and GSTP1 A313G polymorphisms were associated with clinical outcome.

AB - Aims: Oxaliplatin-based chemotherapy for colorectal cancer demonstrates interindividual variability in response, and polymorphisms of ERCC1, ERCC2, XRCC1, GSTP1 and GSTM1 genes may be contributing factors. Additionally, the effect of these genotypes may differ between ethnic groups. Material & Methods: A meta-analysis of the association between these genotypes and response, progression-free survival and overall survival (OS) for patients with colorectal cancer treated with oxaliplatin-based therapy is reported. Results: ERCC1 C118T (TT vs CC OS [hazard ratio (HR): 2.59; p = 0.001]), ERCC2 A2251C (CC or AC vs AA OS [HR: 1.53; p = 0.04]) and GSTP1 A313G (GG vs AA OS, [HR: 0.47; p < 0.001]) polymorphisms were associated with survival. The effect size may be larger for ERCC1 C118T and XRCC1 G1196A in Asian compared with Caucasian populations. No association was apparent for the GSTM1 genotype. Conclusion: ERCC1 C118T, ERCC2 A2251C and GSTP1 A313G polymorphisms were associated with clinical outcome.

KW - colorectal neoplasm

KW - ERCC1

KW - ERCC2

KW - GSTM1

KW - GSTP1

KW - meta-analysis

KW - oxaliplatin

KW - pharmacogenetic

KW - XRCC1

UR - http://www.scopus.com/inward/record.url?scp=84991279257&partnerID=8YFLogxK

U2 - 10.2217/pgs-2016-0102

DO - 10.2217/pgs-2016-0102

M3 - Review article

SN - 1462-2416

VL - 17

SP - 1725

EP - 1732

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 15

ER -

Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: A meta-analysis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this